Intelligent Antibody Discovery

News

Abeome Receives Grant for AbeoMouse™ Technology

February 10, 2014

Athens, GA – Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $217,860 over 10 months. The grant, titled “Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequencing of Anti-PCSK9 Immune Repertoires” is a Phase 1 grant focused on generating a large number of monoclonal antibodies to human PCSK9, an emerging drug target for the treatment of high cholesterol.

“We are very pleased that the National Heart, Lung and Blood Institute (NHLBI) recognizes the power of our novel approach to rapid monoclonal antibody generation dubbed the AbeoMouseTM, which can identify entire repertoires of functional antibodies,” stated Dr. Richard A. Shimkets, President and CEO of Abeome Corporation.

About the Grant: The grant provides for the generation of a large collection of novel monoclonal antibodies, made using Abeome’s proprietary AbeoMouseTM technology, that neutralize PCSK9 function at high affinity, while also possessing other drug-like properties that can be selected for in advance.

About AbeoMouse™: Abeome’s transgenic AbeoMouseTM platform enables the direct selection of desirable functional antibodies straight from the immune system of an immunized mouse. Traditional technology requires the screening of thousands of antibodies to find a handful with drug-like properties.The direct probing of the AbeoMouseTM can reveal high affinity antibodies that block the function of the target.

About Hypercholesterolemia: Elevated LDL cholesterol is one of the three main risk factors for heart disease, and over 14% of Americans suffer from high cholesterol. Over 200 million Americans take statins daily for the reduction of cholesterol, but statins are now known to contribute to the risk of developing diabetes, in addition to side effects such as memory loss and muscle damage. Current clinical trial findings suggest that suppression of PSCK9 function may be a safer and more effective way of reducing serum cholesterol.

About Abeome: Abeome is a privately-held antibody discovery company focused on the high throughput selection, analysis and synthesis of monoclonal antibodies with a primary objective to develop best-in-class prescription products for the therapeutic antibody market – the fastest growing segment of global drug sales. For more information, please visit www.abeomecorp.com

###

AbeoMouse™and DiSH™, are registered trademarks of Abeome Corporation.